News 2023-03-09
Porton Gets Above-Average S&P Global Environmental, Social, and Governance (ESG) Score
Porton Pharma Solutions Ltd. is proud to announce that it has made the top quartile of the S&P Corporate Sustainability Assessment for the first time. On February 28, S&P Global released a new set of S&P Global ESG Scores, where Porton Pharma scored 29 out of 100. The score is above the industry average and shows Porton’s commitment to sustainable development and integrating the ESG concept into its daily operations.
This achievement is attributed to Porton’s conscientious practices of corporate social responsibility and social welfare initiatives. Focusing on its customers, employees, shareholders, suppliers, environment, and communities, Porton has been striving to continuously enhance its policies and practices in corporate governance, compliance operation, and reliable delivery of products and services.
Porton Chief Executive Officer Oliver Ju is an active supporter and advocate of diversity. Since founding Porton, Oliver has spent extra effort creating a safe and inclusive work environment for people from different backgrounds. In addition to building a workplace where everyone is welcome, Porton seeks to contribute to green development and sustainability to foster an environment conducive to growth. During these trying times, Porton works hard to maintain a sustainable supply chain and integrate an EHS (Environment, Health, and Safety) policy into its corporate processes.
Before achieving this significant S&P Global ESG score, Porton had already been making an impact. Last year, it gained an AA score in CNI ESG ratings, an A+ in IIGH ESG ratings, and a BBB in MSCI ESG ratings. Porton also received multiple ESG awards, including the 2022 Top 100 ESG Chinese Listed Companies and the 2022 Top 10 Chinese Pharmaceutical Listed Companies with the Most ESG Investment Value.
While Porton continues to gain ground in its environmental, social, and governance initiatives, this is only the beginning. Embedded in its DNA is a corporate social responsibility to help clients develop high-impact and life-saving medicines in a sustainable and ethical manner. Given this, Porton is committed to enabling early access to good medicines, ensuring its employees’ health and wellbeing, and establishing transparency with its stakeholders.
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
